Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients (Q46423517)

22 December 2017

title

Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients (English)

1 reference

22 December 2017

1 reference

1 reference

8

Toshihiko Torigoe

1 reference

22 December 2017

Yoshihiko Hirohashi

10

Yoshihiko Hirohashi

1 reference

22 December 2017

Noriyuki Satō

14

Noriyuki Sato

1 reference

22 December 2017

Yasuaki Tamura

11

Yasuaki Tamura

1 reference

22 December 2017

Takayuki Kanaseki

13

Takayuki Kanaseki

1 reference

22 December 2017

Tomohide Tsukahara

12

Tomohide Tsukahara

1 reference

22 December 2017

Goro Kutomi

3

Goro Kutomi

1 reference

22 December 2017

Akari Takahashi

9

Akari Takahashi

1 reference

22 December 2017

Hidekazu Kameshima

1

Hidekazu Kameshima

1 reference

22 December 2017

Tetsuhiro Tsuruma

2

Tetsuhiro Tsuruma

1 reference

22 December 2017

Yuji Iwayama

5

Yuji Iwayama

1 reference

22 December 2017

Yasutoshi Kimura

6

Yasutoshi Kimura

1 reference

22 December 2017

author name string

Hiroaki Shima

4

1 reference

22 December 2017

Masahumi Imamura

7

1 reference

22 December 2017

Koichi Hirata

15

1 reference

22 December 2017

publication date

16 December 2012

1 reference

22 December 2017

published in

Cancer Science

1 reference

22 December 2017

volume

104

1 reference

22 December 2017

page(s)

124-129

1 reference

22 December 2017

issue

1

1 reference

22 December 2017

The functioning antigens: beyond just as the immunological targets

cites work

1 reference

Molecular pathological approaches to human tumor immunology

21 January 2018

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

A new era for cancer immunotherapy based on the genes that encode cancer antigens

21 January 2018

1 reference

Regulators of apoptosis: suitable targets for immune therapy of cancer

21 January 2018

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients

21 January 2018

1 reference

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

21 January 2018

1 reference

Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

21 January 2018

1 reference

Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma

21 January 2018

1 reference

Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.

21 January 2018

1 reference

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

21 January 2018

1 reference

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

21 January 2018

1 reference

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

21 January 2018

1 reference

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

21 January 2018

1 reference

Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.

21 January 2018

1 reference

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients

21 January 2018

1 reference

Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function.

21 January 2018

1 reference

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells

21 January 2018

1 reference

Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination.

21 January 2018

1 reference

IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.

21 January 2018

1 reference

Persistent viral infection elevates central nervous system MHC class I through chronic production of interferons

21 January 2018

1 reference

5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.

21 January 2018

1 reference

An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.

21 January 2018

1 reference

12 December 2020

"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy

1 reference

12 December 2020

Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues

1 reference

12 December 2020

Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors

1 reference

12 December 2020

Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells

1 reference

12 December 2020

Identifiers

DOI

10.1111/CAS.12046

1 reference

22 December 2017

PubMed ID

23078230

1 reference

22 December 2017